European clinical network: autism spectrum disorder assessments and patient characterisation
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605477302 | ||
| 003 | CHVBK | ||
| 005 | 20210128100400.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150801xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00787-014-0648-2 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00787-014-0648-2 | ||
| 245 | 0 | 0 | |a European clinical network: autism spectrum disorder assessments and patient characterisation |h [Elektronische Daten] |c [Karen Ashwood, Jan Buitelaar, Declan Murphy, Will Spooren, Tony Charman] |
| 520 | 3 | |a The United Nations and World Health Organisation have identified autism spectrum disorder (ASD) as an important public health issue across global mental health services. Although a range of tools exist to identify and quantify ASD symptoms, there is a lack of information about which ASD measures are used in different services worldwide. This paper presents data from a large survey of measures used for patient characterisation in major ASD research and clinical centres across Europe collected between June 2013 and January 2014. The objective was to map the use of different instruments used to characterise ASD, comorbid psychopathology and cognitive and adaptive ability for patient diagnostic and characterisation purposes across Europe. Sixty-six clinical research sites diagnosing 14,844 patients per year contributed data. The majority of sites use the well-established Autism Diagnostic Observation Schedule (ADOS) and the Autism Diagnostic Interview (ADI) instruments, though the proportion of sites in Western Europe using the ADI was almost double the rate in Eastern Europe. Approximately half the sites also used the Social Communication Questionnaire (SCQ) and Social Responsiveness Scale (SRS), although use of the SRS was over three times higher in Western Europe compared with Eastern Europe. The use of free/open access measures was lower than commercially available tools across all regions. There are clinical and scientific benefits in encouraging further convergence of clinical characterisation measures across ASD research and clinical centres in Europe to facilitate large-scale data sharing and collaboration, including clinical trials of novel medications and psychological interventions. | |
| 540 | |a Springer-Verlag Berlin Heidelberg, 2014 | ||
| 690 | 7 | |a Autism |2 nationallicence | |
| 690 | 7 | |a Europe |2 nationallicence | |
| 690 | 7 | |a Diagnosis |2 nationallicence | |
| 690 | 7 | |a Screening |2 nationallicence | |
| 690 | 7 | |a Measures |2 nationallicence | |
| 700 | 1 | |a Ashwood |D Karen |u Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK |4 aut | |
| 700 | 1 | |a Buitelaar |D Jan |u Department of Cognitive Neuroscience, Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands |4 aut | |
| 700 | 1 | |a Murphy |D Declan |u Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK |4 aut | |
| 700 | 1 | |a Spooren |D Will |u Psychiatry Disease Area, F. Hoffman-La Roche Ltd, Basel, Switzerland |4 aut | |
| 700 | 1 | |a Charman |D Tony |u Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK |4 aut | |
| 773 | 0 | |t European Child & Adolescent Psychiatry |d Springer Berlin Heidelberg |g 24/8(2015-08-01), 985-995 |x 1018-8827 |q 24:8<985 |1 2015 |2 24 |o 787 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00787-014-0648-2 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00787-014-0648-2 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ashwood |D Karen |u Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Buitelaar |D Jan |u Department of Cognitive Neuroscience, Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Murphy |D Declan |u Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Spooren |D Will |u Psychiatry Disease Area, F. Hoffman-La Roche Ltd, Basel, Switzerland |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Charman |D Tony |u Department of Psychology, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t European Child & Adolescent Psychiatry |d Springer Berlin Heidelberg |g 24/8(2015-08-01), 985-995 |x 1018-8827 |q 24:8<985 |1 2015 |2 24 |o 787 | ||